GeneMatrix

About GeneMatrix

GeneMatrix Inc. is a publicly-traded South Korean biotechnology firm specializing in the molecular diagnostics market. Founded in 2000 by former employees of the conglomerate CJ Cheil Jedang, the company was established with the goal of developing diagnostic products and new therapies through genetic mutation research. The company has been listed on the KOSDAQ stock exchange since 2009, a milestone achieved through technical exemptions.

The core of GeneMatrix's business is the development and sale of multiplex molecular diagnostic kits for infectious diseases. This is accomplished through several proprietary platform technologies, including C-Tag™, which enables the simultaneous detection of multiple pathogens from a single test. Another key technology is Restriction Fragment Mass Polymorphism (RFMP), which diagnoses DNA mutations. The company's business model involves leveraging these technologies to produce high-performance qPCR diagnostic kits for healthcare providers. Revenue is generated from the sale of these medical diagnostic reagents. The company serves a global market, with a focus on areas like respiratory diseases, women's health, and sexually transmitted infections.

A significant product line for the company is NeoPlex™, a series of multiplex real-time PCR tests. This range includes diagnostics for various infectious diseases, such as Human Papillomavirus (HPV), Tuberculosis (TB), and gastrointestinal infections. During the COVID-19 pandemic, the company released the NeoPlex™ COVID-19 test and received emergency use authorization from the U.S. FDA, subsequently becoming a supplier for UNICEF diagnostic kits. Beyond diagnostics, GeneMatrix is also expanding into therapeutics, with research and development efforts focused on vaccines and immunotherapeutic agents for cancer treatment, based on a patented viral vector technology.

The company's history includes several key developments. A research collaboration was established in 2001 with VARIAGENICS to develop molecular diagnostic products for predicting drug responses in cancer treatment. By 2011, GeneMatrix had acquired HBI, a company specializing in biochemical diagnostics. A major U.S. patent for its C-Tag™ multiplex diagnostic technology was obtained in 2019, forming the basis for its NeoPlex™ product developments. The company is led by CEO and President Wangdon Yoo, who has guided its collaborative and strategic decisions.